C1q nephropathy (C1qN) is a rare glomerulopathy mostly seen in children, and presents with nephrotic syndrome (NS). Diagnosis depends on immunoflourescence or immunohistochemical C1q mesangial deposition, excluding other immune-mediated diseases. We retrospectively investigated C1qN incidence, clinicopathological features, and outcome among pediatric NS in our institution.Clinical data, microscopic slides and corresponding tissue blocks of pediatric renal biopsies were retrieved. According to diagnostic criteria for C1qN, 53 pediatric NS renal biopsies were selected for AntiC1qA IHC stain microscopic examination. Clinicopathological features and follow up data were recorded. C1qN incidence was 9.4% among pediatric NS biopsies. Mesangial proliferation was the most common histopathological pattern. Steroid dependency with frequent relapses was the most frequent outcome, with a second line immunosuppressant added, yet without impact on progression. Small sample size hinders coherent conclusions; nevertheless, it indicates that C1qN is a rare cause of pediatric NS. C1qN may require second line immunosupressants more often than non-C1q NS.
C1q nephropathy (C1qN) is an idiopathic glomerulopathy typically presenting in children and young adults 1 . Patients classically present with nephrotic syndrome (NS). The key diagnostic features are dominant or codominant glomerular mesangial C1q deposition evidenced by immunoflourescence studies (IF), or immunohistochemical stain (IHC) for antiC1q; provided that other immune complex glomerulonephritides like lupus nephritis are excluded by clinical and serologic tests 2 . Large-scale case studies of C1qN are sparse, with controversy regarding the prognosis and proper patient management.
Examination of C1q deposition by IF or IHCs are currently not performed in our institution, thus, the exact incidence of C1qN and its prognosis is unknown. We aimed to investigate in retrospect using IHC, the prevalence of C1qN in the pediatric renal disease population attending renal pediatric services during the period from 2003 to 2016; and to determine the impact of C1qN on disease course and patient outcome especially the risk of progression to chronic renal failure at final follow up, providing clinicopathological correlation that can be implemented for therapeutic purposes.
Material and Methods
In this retrospective analysis, clinical data were gathered from selected pediatric renal patient's medical papers and electronic records following approval from Faculty of Medicine and University Hospital IRB ethics committee/ report number(KT/14/2014) according to ethical institutional protocols. A total of 105 renal biopsies were found. Gathered data included age, sex, clinical presentation, serum creatinine at presentation and at final follow up, proteinuria at initial diagnosis and at final follow up, histopathological features, IF results, type of therapy, response to treatment, overall follow up period, and final outcome.
A group of clinical definitions were used to verify the data 2 : NS is a triad of heavy proteinuria, hypoalbuminemia and edema. Steroid therapy is the mainstay of NS therapy according to the International Study of Kidney Disease in Children (ISKDC) regimen. Initial episodes are usually treated with prednisolone dose of 60 mg/m 2 daily for 4 weeks and followed by 40 mg/m 2 on alternate days for a further 4 weeks. Nephrotic proteinuria is defined as ≥50 mg/kg/day or ≥ 40 mg/m 2 / day. Response to primary (steroid) treatment was classified as either: steroid sensitive (SS): complete remission of proteinuria during the treatment and the remission persisted for at least 2 months after stopping steroids; steroid dependent (SD): is the occurrence of a relapse while the child is still on steroid treatment or within 2 weeks after its cessation; and steroid resistant (SR), defined as no remission over a period of at least 4 consecutive weeks of steroid therapy. Final patient outcome was set according to clinical information and laboratory values are as follows: Remission: a ≥ 0.15 g/24 h reduction in urine protein concentration. Relapse was defined as reappearance of proteinuria on at least 3 consecutive days. Frequent relapse (FR) was defined as 2 relapses in 6 months or ≥4 relapses in 12 months.
For the 105 renal biopsies, de-identified, hematoxylin &eosin-stained microscopic glass slides and the corresponding paraffin-fixed tissue blocks were retrieved from the archives of pathology department. The slides were reviewed by a nephropathologist.
According to a set of diagnostic criteria for C1qN as determined by Jennette et al. 1 Three samples were initially excluded for being inadequate for evaluation. Categorization of cases (n=102) was then performed as previously mentioned into Group 1(criteriapositive; n=59) and Group 2(criteria-negative; n=43). In Group 1, six tissue blocks were excluded because they were either not found or considered destitute to perform IHC. Accordingly, a total of 53 biopsies (Group 1) were selected to perform the anti-C1q IHC staining as described below.
IHC stains were performed manually on the corresponding tissue blocks, using AntiC1qA antibody [clone: EPR2980Y] Rabbit IgG monoclonal concentrated antibody (Gennova/ Spain). For the formalin-fixed, paraffinembedded tissue, a concentration of 1 µg/ml was used. Heat-mediated antigen retrieval was done before commencing with IHC protocol. Positive and negative tissue controls were run with each set of slides. The results were interpreted by a nephropathologist using a LM, including the presence or absence of glomerular stain, stain intensity, and location within the glomeruli.
Clinicopathological correlation was performed using the LM findings, C1q deposition, and the clinical parameters of the corresponding cases, with center of attention on the mode of therapy, response to treatment, disease progression and outcome. Descriptive statistics of mean was used for continuous variables, and numbers (percentages) for categorical variables.
Results

Diagnostic categories of renal biopsies among pediatric cases
The pediatric renal biopsies included 102 native kidney biyopsies and 3 kidney transplant biopsies.The patients were 51 females and 54 males (ratio of 0.95:1). The mean age was 7.4 years (ages ranged from 3 months to 18 years). Clinical follow up (FU) was available for 96 cases. The follow up periods (FUP) ranged from 1to 156 months (mean= 38.56mo). According to clinical presentation and initial laboratory work up, the most common presentation was nephrotic-range proteinuria (N.Pr) in 59 patients (57.9 %), 39 others had non-nephrotic proteinuria, and 18 had no proteinuria. Ten patients initially presented with renal failure (9.5% of all). Initial serum creatinine (Cr) values ranged from 0.09 to 5.78 mg/dl (0.66± 0.96). Cr readings at final follow up (FFU) ranged from 0.04 to 13.50 mg/dl (1.56± 2.55). Initial urine tests showed no hematuria in 83 cases, microscopic hematuria in 6, and macroscopic hematuria in 13 patients. 3 patients presented initially with hypertension (HTN). Two patients had renal anatomical defects (posterior urethral valves) in addition to nephrotic range proteinuria.
Among the 59 cases selected for the current study, 6 were excluded since the tissue blocks were not found or considered meager for staining (n=59-6= 53). Out of the 53 cases, 40 cases had a histopathological diagnosis of MP (75.5 %), 8 had FSGS (15.1 %), 7 had MCD (13.2 %), with one had NS post renal allograft, 2 cases of congenital nephrotic syndrome, 2 cases with crescentic GN.FU of biopsied NS cases showed the most common outcome to be remission (41%). Persistent proteinuria was observed in 18%, and 16% eventually progressed to ESRD. Clinical data of cases with and without C1q detection are summarized in Table I . Figure 1 . One paraffin-fixed tissue block for one C1q-positive sample was de-parafinized for electron microscopic (EM) examination by transmission electron microscope, following retrieval procedures, and the glomeruli showed mesangial immune deposits, as shown in Figure 2 . Due to the small number of samples that were C1q +, statistical analysis was not justified; however, the clinicopathological features of those cases are detailed below.
Results of IHC with anti-
Clinicopathological features of C1q+ cases
Our case series included 5 patients (n=5). The patient ages ranged from 2 to 12 years (mean = 7.4 years). 
Patient 1
A 12-year-old boy, presenting with edema and N.Pr, was initiated on prednisolone therapy but did not complete his therapy course and was discharged from hospital by family against 
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medical advice. Unfortunately, he was LFU and upon medical archive retrieval was found to be dead due to renal failure.
Patient 2
The patient is a 6-year-old boy, who presented to pediatric clinics with NPr. He was treated with steroids and his clinical course was significant for SD. Second line drug (cyclosporine) was added after 2 yrs. He had his last relapse on June 2008 after 4 years of initial diagnosis. At final FU, he was found well with no proteinuria.
Patient 3
A 5-year-old male presented with NS/SD, his serologic work up showed normal serum C3. His disease course was significant for FR. Cyclosporine as a second line drug was added after 3 yrs on Nov, 2008. He was last seen on Dec, 2009, when he was doing well 1 year after last relapse.
Patient 4
A 2-year-old female with NS/SD, started on steroids initially, then cyclophosphamide was added 6 months later. She was still symptomatic at her final follow up, when she started to develop resistance to both steroids and cyclophosphamide. She also complained of precocious puberty 2 years since her initial diagnosis.
Patient 5
A 12-year-old male, presenting with 3+ urine dipstick protein, was evaluated and treated with steroids. An outside electron microscopic report for his kidney biopsy was suspicious of Fabry's disease, which is a lysosomal storage disease that frequently leads to proteinuria and progression to renal failure by adulthood 3 . During the FUP of 48 months his clinical course was significant for many admissions, NS-SD, and had FR. Cyclosporine was added 24 months of initial diagnosis as a steroid sparing agent. Tullus et al. 16 Roberti et al. 15 Wong et al. 14 
Discussion
Fukuma et
al. 13 Kernisk et al. 12 Lau et al. 11 Iskandar Due to the recent awareness of C1qN and its rarity, the number of comprehensive large-scale studies on C1qN had been modest. Besides some case reports and small adult case series, there had been eight exclusively pediatric case series of C1qN. [9] [10] [11] [12] [13] [14] [15] [16] [17] Major clinicopathological parameters of those pediatric case series are summarized in Table II .
Generally, the incidence of C1qN shows a broad range among different pediatric and adult studies, ranging from as low as 0.2% to as high as 16.5% in pediatric cases with persistent NS. 6, 12 Our study had an incidence of 9.4% among pediatric NS cases. The wide spectrum of incidence among the different studies is due to the study population, as it is much higher in NS patients compared to random studies on general biopsy populations. Another recent study from Middle East, focusing on SR-NS patients, had showed that the incidence of C1qN was about 8%. 18 The mean age among those studies ranges from as young as 2.3 to 10.7 yrs.The gender distribution had moved back and forth in favor of male gender in 4 previous studies, while it had a female predominance in 3 others, and showed equal incidence in one other study.
The optimal management of C1qN is not clearly defined yet. Corticosteroids have been used as a first line with diverse results, with some studies showing poor response to oral corticosteroid therapy 10 , while others shows superior results. 14 There had been substantial disagreement over the outcome of patients with C1qN.
As it had been previously described, the outcomes of patients with C1qN can be predicted by an array of clinical and histopathological variables. 6 Precautious evaluation of the previous pediatric case series makes it clear that the dominant LM pattern had a higher impact in predicting disease progression and outcome at FFU, even regardless of C1q deposition. 8 Tulluset al. 16 had confirmed that cases presenting with a LM picture of MCD had better general outcome compared to those with FSGS, or MP. They also show better response to steroids, although not statistically significant. 16 Nevertheless, patients with MCD/C1q deposition seemed to need second-line drugs as cyclosporine despite having comparable renal outcome at FFU. 14 Regarding overall disease progression to ESRD, some studies failed to show any statistical significance distinguishing cases with C1q from non-C1q patterns, and both patient groups exhibited an analogous outline. 16 In conclusion, our current study had comparable results to previous pediatric case series in clinical and histologic parameters. MP was the most common LM pattern. All cases presented clinically as NS. SD-NS was the most frequent outcome, however, with no statistical impact on progression to renal failure. The small number in our study hinders accurate statistical assurance, however, our findings also point towards a superior role of LM pattern over C1q deposits regarding disease progression. It may, also signify need of second line drugs in C1qN. Larger studies are needed to establish solid management guidelines of C1qN.
